Navigation Links
Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
Date:11/4/2007

Largest study to date finds no difference in heart attack or mortality rates

SUNDAY, Nov. 4 (HealthDay News) -- In the largest study of its kind to date, Harvard researchers report that they have found drug-eluting stents pose no more risk of heart attack or death than bare metal stents do.

"There has been a long debate about the safety of drug-eluting stents," said lead investigator Dr. Laura Mauri, an assistant professor of medicine at Harvard Medical School and Brigham & Women's Hospital, in Boston. "It was very reassuring to see that there was not an increased rate of death or heart attack."

Mauri presented the findings during a news conference Sunday at the American Heart Association annual meeting in Orlando, Fla.

People who have blocked heart arteries often undergo a procedure called angioplasty, or percutaneous coronary intervention (PCI). A small tube called a catheter is inserted into the blood vessel, then a balloon on the tip of the catheter is inflated to open the blockage and restore blood flow. Typically, a stent, or tiny wire scaffold, is also inserted to keep the vessel open. However, stents carry the risk of blood clots forming within them -- a potentially dangerous condition called stent thrombosis.

It's clear that drug-eluting stents reduce the probability that a patient will need to undergo a repeat procedure within a year. However, there has been heightened concern in the medical community in the past year that coated stents seem to raise the risk of thrombosis.

"Drug-eluting stets reduced the need for revascularization procedures," Mauri said. "What's not clear is what are the long-term consequences of placing a drug-eluting stent versus a bare metal stent in a general population."

This trial took advantage of a statewide registry of people undergoing PCI procedures in Massachusetts.

"In Massachusetts, all patients who undergo stenting procedures, b
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Drug-Coated Stent
2. Failure of Drug-Coated Stent
3. Stronger Backing for Drug-Coated Stents
4. Drug-Coated Stents – Proven to be More Effectiv
5. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
6. Drug-coated heart stents under scrutiny, after study
7. Off-label and Untested Use of Drug-coated Stents Appears Widespread
8. Studies Reveal Inappropriate Use Of Drug-Coated Stents
9. Expandable metal stents used in digestive cancers
10. The Efficacy Of Newer Stents Questioned
11. Analyzing The Side Effects Of Sirolimus Stents
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
(Date:2/27/2015)... patients die annually as a result of preventable medical harm—this ... each day. Now more than ever before, hospitals and patients ... they can to stay safe. , Through an exclusive ... discusses the importance of safer hospitals. “It’s incumbent upon all ... ensure that all our patients are in the safest environment ...
(Date:2/27/2015)... 27, 2015 Muscular Dystrophy Association ... Engineering at Duke University, recently announced a potentially ... young men with Duchenne muscular dystrophy (DMD). The ... and Gersbach will discuss their implications at MDA's ... in Washington, D.C. , Background: Gersbach and ...
(Date:2/27/2015)... 2015 Over 440,000 patients die each year ... now to educate readers on how they can take control ... serve as a guide to educate and inspire readers to ... loved ones safe with tips on topics ranging from hospital ... cover of the print publication. He recently spoke to ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 With cases of ... Dade area, concerned parents look to school administrations to help ... screenings. Though head lice is a common parasite that passes ... a nuisance, causing parents and teachers significant distress. , ... screenings at the school. This would allow parents and ...
(Date:2/27/2015)... Schenectady, New York (PRWEB) February 27, 2015 ... has been named one of the Best Companies to ... , “Transfinder recognizes the importance of creating a great ... a demanding – yet professionally fulfilling – environment. There’s ... doing great work together,” said Antonio Civitella, president and ...
Breaking Medicine News(10 mins):Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2Health News:Statement: New MDA-Funded Genetic Therapy Technique Targets DMD 2Health News:Safe and Sound: Improving Patient Outcomes through Mediaplanet’s “Patient Safety” Campaign 2Health News:South Florida Parents Put Pressure on Schools to Perform Lice Screenings to Prevent Spread of Lice According to One Miami Lice Removal Company Called Lice Troopers 2Health News:Transfinder Named a Best Company to Work for in New York State 2
... PLC (OTC,Bulletin Board: SNKTY), a Life Sciences company ... science of healthy aging, today announced,that its North ... an,amount up to $28 million to further advance ... including Invicorp(R)., Plethora Solutions Holdings PLC, a ...
... the POA, indicator reporting requirements by implementing data elements that expand, ... healthcare ... claims., ... their commitment for continuous improvement is,evident by assisting clients with compliance ...
... for future of loved ones with special ... ... Mutual,Life Insurance Company (MassMutual) today made available on its Web site a,free ... begin,developing or supplementing life care plans for family members with a,disability or ...
... ... With U.S. Presence, AMSTERDAM, The Netherlands, ... evolving field of cancer molecular diagnostics,today announced the appointment of Richard ... medical officer (CMO). Dr. Bender, who,will report directly to Chief Executive ...
... The U.S. Agency,for International Development (USAID) highlights ... the Agency,s community partnerships,in Africa as part of ... this,week. Admiral Timothy Ziemer, U.S. Malaria Coordinator, and ... join Jay Hein,Director of the White House Office ...
... the California NanoSystems Institute at UCLA have developed a novel ... inside tiny pores and release them into cancer cells in ... "nanoimpeller," the device is the first light-powered nanomachine that operates ... for cancer treatment. , UCLA researchers reported ...
Cached Medicine News:Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 2Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 3Health News:Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts 4Health News:Data Dimensions Assists Clients With Compliance of 'Present on Admission' (POA) Indicator Reporting Requirements as Part of the April 1, 2008 Timeline 2Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 2Health News:MassMutual Offers Free 'Letter of Intent' Template to People with Disabilities and Their Families, Caregivers 3Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 2Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 3Health News:USAID Participates in White House Office of Faith-Based and Community Initiatives Conferences in Rwanda and Zambia 2Health News:UCLA researchers design nanomachine that kills cancer cells 2Health News:UCLA researchers design nanomachine that kills cancer cells 3
(Date:2/27/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today announced that it ... Tuesday, March 10, 2015. Rob Kill , President ... Officer, will present at 4:00 p.m. Pacific Time and ... at the Ritz Carlton in Laguna Niguel, ...
(Date:2/26/2015)... DALLAS , February 27, 2015 ... Review, H2 2014 market research report to its ... the Corneal Ulcers, therapeutic pipeline. The ... information on the therapeutic development for Corneal Ulcers. ... infections that includes bacterial infections, viral infections & ...
(Date:2/26/2015)... 26, 2015  Mobility Ventures LLC, an AM General ... of America (NYSE: BAC ) that will ... of the revolutionary MV-1 - - the world,s first ... up to provide safe and comfortable transportation for all ... loan to purchase a new MV-1 vehicle at the ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... The Netherlands, July 16 Neurofeedback - also,called EEG ... activity in order to,normalize Brain function and treat psychiatric ... 10 years, however the question,whether this treatment should be ... a study will be published in the scientific,journal ,EEG ...
... , , BOSTON and ... IIb multinational study(1) with edoxaban(2) - an investigational oral Factor ... atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer ... The analysis finds that bleeding associated with edoxaban is most ...
Cached Medicine Technology:New Research Shows: Neurofeedback is an 'Evidence-Based' Treatment for ADHD 2Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 2Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 3Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 4Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 5